Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
In what scenario would you opt to perform an MRI-PDFF in a patient with MASLD/MASH or in whom you suspect has this? Why would you opt for this over a Fibroscan or other NILDA?
Related Questions
In what kind of patient scenario would you consider testing for inherited disorders of lipid metabolism in the evaluation of a patient with MASLD? What are you looking for clinically and in their workup and how do you proceed?
If you do not have easy access to shear wave elastography (aka Fibroscan), what do you recommend for non-invasive tests to determine if a MASLD patient has clinically significant portal hypertension and risk-stratify them?
What is your approach to the use of lipoprotein(a) as part of the cardiometabolic profile of a patient suspected to have or with MASLD/MASH?
How would you manage a patient who presents with hair loss that began after they started a GLP-1 inhibitor?
How would you approach GLP-1/GIP agonist use for MASLD management in a patient who had a prior episode of pancreatitis?
How long do you typically treat patients with phentermine for weight loss and what clinical markers do you follow?
How do you incorporate other pharmacologic bariatric/appetite suppressants in the context of their clinical care plan for MASLD?
In a patient with low (or normal) BMI but findings of steatosis on imaging, no cardiometabolic comorbidities, and very elevated CAP scores, what are your next diagnostic and therapeutic steps to identify the cause of their steatosis and subsequent management?
What is your approach on the pursuit of bariatric surgery in a patient with advanced fibrosis?
What clinical, imaging, or serologic markers would be an indication to you to stop GLP-1 therapy for management of MASLD?
